GLOBAL HEALTH | GLOBAL PARTNERSHIPS | GLOBAL IMPACT

Research > CVD Prevention and Risk Factors

Photo for ACHIEVE

ACHIEVE

Official Title

Aldosterone bloCkade for Health Improvement EValuation in End-stage renal disease

Status

Ongoing

Overview

Globally, over 2 million people receive dialysis for end-stage renal disease (ESRD) and 650,000 new patients start dialysis each year. Furthermore, the number of patients receiving dialysis is increasing as access to dialysis in the developing world improves and the prevalence of diabetes and vascular disease rises. Despite technical advances in dialysis, the outcomes for patients with ESRD are poor. Patients have frequent hospitalizations, poor health related quality of life and strikingly, high mortality rates.

The most common cause of death in patients receiving dialysis is cardiovascular disease, accounting for 40% of all deaths. Observational studies suggest a causal pathway to cardiovascular death that includes progressive ventricular hypertrophy and dilatation as well as accelerated atherosclerosis. These changes result in myocardial ischemia and cardiac fibrosis that, in turn, lead to heart failure, arrhythmias and cardiac arrest. Strongly implicated in this pathophysiology is aldosterone. Mineralocorticoid receptor antagonists (MRAs) in non-ESRD patients, prevent cardiovascular deaths and small randomized controlled trials of MRAs in ESRD suggests they may reduce death and may be safe.

Spironolactone is the most commonly used MRA worldwide. We will conduct a multicentre randomized controlled trial (RCT) to determine if spironolactone reduces cardiac mortality and hospitalizations for heart failure in patients treated with dialysis. This trial is called the Aldosterone bloCkade for Health Improvement EValuation in End-stage renal disease (ACHIEVE).

Study Design

A randomized controlled trial with active run-in

Primary Endpoint

To determine if spironolactone reduces cardiac morbidity and mortality for patients treated with chronic dialysis.

Number of Patients

2750

Number of Sites

200

Number of Countries

10

Study Period

2017-2020

Principal Investigator

Michael Walsh

Program Manager

Jessica Tyrwhitt

Research Coordinator

Joanne Wilkinson